Health CarePharmaceuticals & Biotechnology
  • Price (USD)3.41
  • Today's Change-0.12 / -3.40%
  • Shares traded215.71k
  • 1 Year change-6.52%
  • Beta0.8554
Data delayed at least 15 minutes, as of Jul 21 2017 21:00 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

Analyst consensus information is not available for CTI BioPharma Corp.
  • 1yr ago
  • 3M ago
Select bar for recommendation details.

Earnings history & estimates

On Mar 02, 2017, CTI BioPharma Corp reported 4th quarter 2016 losses of -0.23 per share. This result exceeded the -0.600 consensus loss of the one analyst covering the company and under-performed last year's 4th quarter results by 82.31%.
The next earnings announcement is expected on Aug 02, 2017.
Average growth rate+17.07%
CTI BioPharma Corp reported annual 2016 losses of -1.86 per share on Mar 02, 2017.
Average growth rate+25.74%
More ▼

Revenue history & estimates

CTI BioPharma Corp. had 4th quarter 2016 revenues of 9.14m. This bettered the 700.00k estimate of the one analyst covering the company. This was 19.32% below the prior year's 4th quarter results.
Average growth rate+106.09%
CTI BioPharma Corp. had revenues for the full year 2016 of 57.41m. This was 256.20% above the prior year's results.
Average growth rate+893.09%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.